transformational research: canada 2020 (parkinson’s & related diseases)
goal: to provide funding for translational research that will accelerate the development of therapeutics for neurodegenerative diseases of aging.
funding: a maximum of $1,500,000 over up to 3 years per project. encouraging applications at all funding levels from $300,000 to $1,500,000, without need for preliminary data.
applicant eligibility: eligible principal applicants must be researchers working in canada at least 30% of the time at or above the level of assistant professor or equivalent, and be affiliated with a canada revenue agency-qualified donee institution located in canada. co-applicants/collaborators must be at the post-doctoral level or above and can be working outside canada.
applicants may appear in any role on any number of projects.
project eligibility: projects must meet the following conditions to be eligible:
- be translational research (excluding clinical trials and clinical trial sub-studies) that accelerates the development of therapeutics for neurodegenerative diseases of aging.
- clinical trials and clinical trial sub-studies should be submitted to the early-phase clinical trials or rapid response programs; however other translational research using humans or human samples/data is in scope.
- be the development of a therapeutic and/or tool and/or select complementary approaches (please refer to the program details for more information on complementary approaches that are in scope)